College of Medicine and Department of Radiation Oncology, West Cancer Center, University of Tennessee Health Science Center, Memphis, Tennessee.
Department of Radiation Oncology, West Cancer Center, University of Tennessee Health Science Center, Memphis, Tennessee.
Pediatr Blood Cancer. 2018 Dec;65(12):e27408. doi: 10.1002/pbc.27408. Epub 2018 Sep 30.
Intensification of systemic therapy for high-risk neuroblastoma (HRNB) has resulted in improved local control and overall survival (OS) leaving potential for de-escalation of primary site radiotherapy. The utility of primary site de-escalation should be evaluated in the context of potential for successful local-regional salvage. We evaluated salvage strategies and outcomes in patients with HRNB with local-regional recurrence as a component of first failure.
Twenty of 89 patients with HRNB experienced local-regional recurrence as a component of first relapse after chemotherapy, radiotherapy, surgery, and stem cell transplant from 1997 to 2013. We reviewed salvage therapy strategies and disease control, and report on the impact of local therapy as salvage for local-regional relapse.
Six of 20 patients with local-regional failure (LRF) were alive after a median follow-up of 13 years (range, 0.9-25.2 years). Median OS was 4.6 years (95% CI, 0.6 to not reached) versus 0.6 years (95% CI, 0.05-2.6) after LRF with and without distant failure, respectively (P = 0.03). OS in patients receiving salvage radiotherapy was comparable to those receiving initial adjuvant but no salvage radiotherapy. Time to first failure and death was significantly impacted by the intensity of frontline systemic therapy (P = 0.03). Salvage radiotherapy reduced the hazard for subsequent LRF (hazard ratio 0.3, 95% CI 0.1-0.9, P = 0.04) but not OS (P = 0.07).
Our study highlights the potential of local control strategies at first failure in patients with LRF when primary site radiotherapy was initially omitted, and delineates potential selection factors which may further improve the therapeutic ratio.
高危神经母细胞瘤(HRNB)的全身治疗强化已导致局部控制和总体生存(OS)得到改善,从而有可能降低原发部位放疗的剂量。在可能成功进行局部区域挽救的情况下,应评估原发部位降级的效用。我们评估了 HRNB 患者中局部区域复发作为首次失败的一部分的挽救策略和结局。
1997 年至 2013 年,89 例 HRNB 患者中有 20 例在化疗、放疗、手术和干细胞移植后出现局部区域复发作为首次复发的一部分。我们回顾了挽救治疗策略和疾病控制情况,并报告了局部治疗作为局部区域复发挽救的作用。
20 例局部区域失败(LRF)患者中有 6 例在中位随访 13 年后(范围,0.9-25.2 年)存活。LRF 伴或不伴远处失败患者的中位 OS 分别为 4.6 年(95%CI,0.6-未达到)和 0.6 年(95%CI,0.05-2.6)(P=0.03)。接受挽救性放疗的患者的 OS 与接受初始辅助治疗但无挽救性放疗的患者相当。一线全身治疗强度显著影响首次失败和死亡的时间(P=0.03)。挽救性放疗降低了随后发生 LRF 的风险(风险比 0.3,95%CI 0.1-0.9,P=0.04),但对 OS 无影响(P=0.07)。
我们的研究强调了在最初省略原发部位放疗时,LRF 患者在首次失败时局部控制策略的潜力,并描述了可能进一步提高治疗比的潜在选择因素。